Search / Trial NCT00001013

Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Trimethoprim Sulfamethoxazole Combination Trimetrexate Aids Related Opportunistic Infections Pneumonia, Pneumocystis Carinii Pentamidine Infusions, Intravenous Leucovorin Drug Therapy, Combination Folic Acid Antagonists Aerosols Acquired Immunodeficiency Syndrome Antiprotozoal Agents Aids Related Complex Sulfamethoxazole Trimethoprim

ClinConnect Summary

New treatments are needed to reduce the mortality rate from PCP in AIDS patients and to reduce the high relapse rate found after conventional therapy. Trimetrexate (TMTX) was chosen for this trial because it was found to be much more potent than sulfamethoxazole/trimethoprim (SMX/TMP) against the PCP organism in laboratory tests. Also TMTX, in combination with leucovorin (LCV), did not cause severe toxicity in a preliminary trial. It is believed that TMTX will be more effective than SMX/TMP in treating PCP and in preventing a recurrence of PCP. Preliminary studies suggest that aerosolized p...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • * Acetaminophen:
  • 650 mg prescribed as necessary for temperature \> 38.7 degrees C. Acetaminophen should not be prescribed as a standing order for more than 48 hours.
  • Prior Medication:
  • Allowed:
  • Zidovudine (AZT) as long as such therapy is suspended prior to randomization and not reinstituted until therapy for the acute episode is completed and the patient's white blood cell count is acceptable.
  • Other myelosuppressive therapies which may be handled in the same manner as AZT.
  • Prophylaxis for Pneumocystis carinii pneumonia (PCP).
  • Unequivocal diagnosis of Pneumocystis carinii pneumonia (PCP) by morphologic confirmation of three or more typical P. carinii organisms in sputum, bronchoalveolar lavage fluid, or lung tissue obtained by transbronchial or open-lung biopsy within 3 days before or after randomization. If morphologic confirmation is not possible prior to therapy, patients may be randomized if the investigator believes there is a high suspicion of PCP based on clinical presentation. If morphologic diagnosis cannot be established within 6 days of randomization, the patient will be withdrawn from study therapy. Resting (A-a) DO2 \< 30 torr on room air. Patient, parent, guardian, or person with power of attorney gives informed consent.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients will be excluded for the following reasons:
  • History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reaction secondary to antibiotics containing sulfa, trimethoprim, or trimetrexate.
  • History of life-threatening pentamidine toxicity.
  • Concurrent Medication:
  • Excluded:
  • Other drugs for the treatment or prevention of AIDS or Pneumocystis carinii pneumonia (PCP).
  • Disalcid.
  • Aspirin.
  • Acetaminophen q4h as a standing order for more than 48 hours.
  • Prior Medication:
  • Excluded within 14 days of study entry:
  • Systemic steroids exceeding physiological replacement.
  • Other investigational drugs including ganciclovir.
  • * Excluded within 6 weeks of study entry:
  • Another antiprotozoal regimen for this episode for therapy of active Pneumocystis carinii pneumonia (PCP).
  • Patients who are unable to have arterial blood gas analysis (ABG's) on room air.
  • Patients for whom a liter of intravenous fluid (5 percent dextrose in water) per 24 hours, which is required to maintain blinding, would be medically inadvisable.

Trial Officials

Sattler FR

Study Chair

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Los Angeles, California, United States

Bronx, New York, United States

New York, New York, United States

West Columbia, South Carolina, United States

Chicago, Illinois, United States

Worcester, Massachusetts, United States

Rochester, New York, United States

Miami, Florida, United States

Bronx, New York, United States

Bronx, New York, United States

Buffalo, New York, United States

Elmhurst, New York, United States

Stony Brook, New York, United States

Syracuse, New York, United States

New York, New York, United States

New Orleans, Louisiana, United States

New Orleans, Louisiana, United States

New Orleans, Louisiana, United States

Washington, District Of Columbia, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

Hershey, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials